An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination Engineering

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other pathogens with pandemic potential requires safe, protective, inexpensive, and easily accessible vaccines that can be developed and manufactured rapidly at a large scale. DNA vaccines can achieve these criteria, but induction of strong immune responses has often required bulky,...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Engineering, Immunology and Inflammation, Coronavirus (COVID-19) Biological Sciences Source Type: research

Related Links:

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve as a global health crisis. Although highly effective vaccines have been developed, non-pharm...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Study protocol Source Type: research
Rich nations are again raising barriers to ending the pandemic – politicians, globally, must follow the science and act togetherDr Ayoade Olatunbosun-Alakija is the co-chair of the African Union ’s Africa Vaccine Delivery AllianceThe advent of the Omicron variant has given us a glimpse of an alternative future in which, had the Sars-CoV-2 virus been initially identified in Africa in early 2020, the world would have maybe locked Africa away. There would have been no emergency funding for vaccine development, limited global attention, and Africa would have become known as the continent of Covid.We may never know ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Africa Coronavirus World news Science Source Type: news
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.PMID:34859883 | DOI:10.26355/eurrev_202111_27271
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: Source Type: research
Basel, 3 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB Molbiol, a newly acquired subsidiary within the Roche Diagnostics division, have added three additional Research Use Only (RUO) test kits for the detection of mutations present in the novel B.1.1.529 Omicron SARS-CoV-2 variant: VirSNip SARS Spike ins214EPE (RUO), VirSNiP SARS-CoV-2 Spike S371L S373P (RUO), VirSNip SARS Spike E484A (RUO). The World Health Organization (WHO) has classified the recently emerged SARS-CoV-2 variant, Omicron (B.1.1.529), as a COVID-19 variant of concern (VOC).The VirSNiP variant kits allow differentiation between unique mutation...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Biochem Soc Trans. 2021 Dec 2:BST20210859. doi: 10.1042/BST20210859. Online ahead of print.ABSTRACTThe novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than 200 million people have been infected with the virus and 4.3 million have lost their lives. Various monoclonal antibodies of human origin that neutralize the SARS-CoV-2 infection have been isolated from convalescent patients for therapeutic and prophylactic purposes. Several vaccines have been developed to restrict the spread of the virus and have been rap...
Source: Biochemical Society Transactions - Category: Biochemistry Authors: Source Type: research
This study paves the way towards discovering a lead used in the treatment of COVID-19 from natural sources and introduces phytomedicines with dual therapeutic effects against COVID-19 besides their original pharmacological effects. We recommend further in vitro evaluation of their anti-COVID-19 activity and future clinical studies.PMID:34855180 | DOI:10.1007/s11356-021-17642-9
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Source Type: research
Biochem Soc Trans. 2021 Dec 2:BST20210859. doi: 10.1042/BST20210859. Online ahead of print.ABSTRACTThe novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than 200 million people have been infected with the virus and 4.3 million have lost their lives. Various monoclonal antibodies of human origin that neutralize the SARS-CoV-2 infection have been isolated from convalescent patients for therapeutic and prophylactic purposes. Several vaccines have been developed to restrict the spread of the virus and have been rap...
Source: Biochemical Society Transactions - Category: Biochemistry Authors: Source Type: research
More News: Academies | Allergy & Immunology | Coronavirus | COVID-19 | Pandemics | Respiratory Medicine | SARS | Science | Vaccines